KRS Capital Management LLC Buys 280 Shares of DexCom, Inc. (NASDAQ:DXCM)

KRS Capital Management LLC lifted its stake in DexCom, Inc. (NASDAQ:DXCM) by 11.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,680 shares of the medical device company’s stock after buying an additional 280 shares during the period. KRS Capital Management LLC’s holdings in DexCom were worth $372,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Capital World Investors lifted its stake in DexCom by 130.7% during the fourth quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock worth $1,151,392,000 after purchasing an additional 5,256,092 shares during the last quarter. Norges Bank bought a new stake in DexCom during the fourth quarter worth $540,178,000. Artisan Partners Limited Partnership lifted its stake in DexCom by 164.8% during the fourth quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock worth $732,169,000 after purchasing an additional 3,672,471 shares during the last quarter. Capital Research Global Investors lifted its stake in DexCom by 21.4% during the fourth quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock worth $1,898,085,000 after purchasing an additional 2,695,296 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA bought a new stake in DexCom during the fourth quarter worth $231,773,000. 97.75% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have weighed in on DXCM. UBS Group upped their target price on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Raymond James increased their price target on DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research note on Friday, April 26th. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a research note on Monday, June 10th. Redburn Atlantic began coverage on DexCom in a research note on Thursday, May 30th. They issued a “neutral” rating and a $130.00 price target for the company. Finally, Citigroup increased their price target on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Four equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and an average target price of $140.33.

DexCom Stock Down 1.0 %

Shares of DXCM traded down $1.16 during trading hours on Friday, hitting $113.38. The stock had a trading volume of 5,429,492 shares, compared to its average volume of 3,129,523. DexCom, Inc. has a 1-year low of $74.75 and a 1-year high of $142.00. The firm has a market capitalization of $45.09 billion, a P/E ratio of 73.15, a price-to-earnings-growth ratio of 2.80 and a beta of 1.22. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.90 and a quick ratio of 2.53. The firm has a 50 day simple moving average of $123.14 and a 200-day simple moving average of $125.66.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.27 by $0.05. DexCom had a net margin of 16.82% and a return on equity of 31.01%. The firm had revenue of $921.00 million for the quarter, compared to analysts’ expectations of $911.20 million. Sell-side analysts predict that DexCom, Inc. will post 1.78 EPS for the current fiscal year.

Insider Transactions at DexCom

In other news, Director Bridgette P. Heller sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $113.55, for a total transaction of $113,550.00. Following the completion of the sale, the director now owns 25,349 shares in the company, valued at approximately $2,878,378.95. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CFO Jereme M. Sylvain sold 745 shares of DexCom stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $115.05, for a total value of $85,712.25. Following the completion of the transaction, the chief financial officer now directly owns 84,948 shares in the company, valued at approximately $9,773,267.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bridgette P. Heller sold 1,000 shares of DexCom stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $113.55, for a total transaction of $113,550.00. Following the completion of the transaction, the director now owns 25,349 shares of the company’s stock, valued at $2,878,378.95. The disclosure for this sale can be found here. Insiders sold a total of 55,735 shares of company stock worth $7,619,347 in the last quarter. Insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.